TME Pharma has entered a binding exclusive negotiation agreement with Japanese biotech TMS Co., Ltd. to develop and commercialize NOX-A12 for glioblastoma. TME Pharma receives €150,000 for exclusivity and expects around €10 million upfront plus over €100 million in milestones and 8-10% royalties on sales projected to reach $1 billion. The partnership aims to resume the Phase 2 GLORIA study quickly, leveraging favorable market conditions and TME Pharma's Fast Track and Orphan Drug designations. This deal could significantly extend TME Pharma's financial runway and create substantial shareholder value if clinical results continue to be positive.
TME Pharma's new agreement with Japanese TMS Co., Ltd. provides context for health sector activity on Pluang. For readers following health stocks, here is Pluang's market snapshot as of Oct 29, 2026 14:11 WIB: out of 150 priced US health stocks, 105 rose and 42 fell. Notable movers include BBIO at USD 71.96 with a 3.73% increase and 100% sell order activity, WGS at USD 65.07 up 3.71% with 55% buy orders, and HLN at USD 9.74 down 3.37%. Typical hold times on Pluang range from 15 to 64 days among these stocks.
DNO ASA, a Norwegian oil and gas company, announced a cash dividend of NOK 0.375 per share to be paid around November 17, 2026. Shareholders registered by November 9, 2026, will receive the dividend, with shares trading ex-dividend starting November ...
TGS ASA announced that its shares will be traded ex-dividend at NOK 1.45 per share starting October 29, 2026. This means investors buying the stock from this date will not receive the upcoming dividend payment. The dividend distribution follows appro...
Metaplex (MPLX) surged 36.62% on October 29, significantly outperforming the broader NFT sector, which rose 2.56%. This sharp rally followed a period of low trading activity but lacked a clear catalyst such as a project update or announcement. Metapl...
A data leak revealed records connecting 4,580 swap orders to public blockchain deposits, Monero destinations, and client IP addresses. This leak allows tracing transaction activity across networks by linking a public-chain deposit, the Monero exchang...
TME Pharma has entered a binding exclusive negotiation agreement with Japanese biotech company TMS Co., Ltd. for the global rights to NOX-A12, a drug targeting glioblastoma brain cancer. TMS will create a subsidiary to fund and advance clinical devel...
